logo
Exercise best bet for people with chronic lymphocytic leukaemia

Exercise best bet for people with chronic lymphocytic leukaemia

Hans India7 days ago
Chronic lymphocytic leukaemia (CLL) is the most common adult blood cancer in the western world, and it predominantly affects older adults. Most people are diagnosed after the age of 70, but increasing numbers of younger people, some under 60, are also being affected.
CLL starts when a type of immune cell called a B cell – normally responsible for producing antibodies – becomes cancerous. This not only stops it from working properly but also weakens the rest of the immune system. For many people, CLL begins as a slow-moving, low-grade disease that doesn't need immediate treatment.
These patients are placed on 'active monitoring,' where they're regularly checked for signs of progression. Others, especially those with more aggressive forms of the disease, will need immediate and targeted treatment to destroy the cancer cells. But regardless of the stage, CLL involves a prolonged and often unpredictable course.
It is associated with a higher risk of infections, secondary cancers and a heavy symptom burden that can affect quality of life for years. People on active monitoring often find themselves in a kind of medical limbo: well enough not to need treatment, but not well enough to feel secure. Fatigue, anxiety, social isolation and fear of infection are common. For those receiving treatment, side effects including nausea, bleeding, diarrhoea and extreme tiredness can make everyday life even more challenging. Because CLL weakens the body's ability to fight infection, many people begin avoiding places where germs might spread: busy shops, family gatherings, even the gym. But while this instinct is understandable, it can come at a cost.
Over time, isolation and inactivity can chip away at physical fitness, reduce resilience and make it harder to recover from illness or cope with stress. The role of exercise is good for everyone but for people living with CLL, it can be life changing.
Our research shows that physical activity is strongly linked to fewer symptoms and a better quality of life. Fatigue, the most common and often most debilitating symptom, was significantly lower in people who stayed active. Many also reported reduced pains and a greater sense of physical wellbeing.
Cancer-related fatigue isn't just feeling a bit tired. It's a deep, persistent exhaustion that doesn't improve with sleep or rest. The exact biological reasons behind it aren't fully understood, but one thing is clear: regular movement helps. People who are more active tend to feel better – and live better. The good news is that even gentle activity can make a difference. Low-intensity activities are safe for almost everyone and come with meaningful health benefits. Walking, yoga, swimming – anything that gets you moving – can help ease symptoms. In fact, research shows that just 12 weeks of regular exercise can reduce fatigue and improve day-to-day wellbeing. People with additional health concerns, such as heart disease, diabetes or bone conditions, should take extra care. It's always a good idea to speak to a doctor or physiotherapist before starting a new routine.
The PAR-Q+ (physical activity readiness questionnaire) is a helpful tool to assess whether it's safe to begin exercising. Once cleared, the goal is to work up to the recommended activity levels: 150–300 minutes of moderate activity a week (like brisk walking or cycling) or 75–150 minutes of vigorous activity (like jogging or swimming), along with two sessions of muscle-strengthening activities per week. Start slowly and build gradually. Because people with CLL are immunocompromised, it's important to reduce infection risks while staying active. That might mean exercising outdoors, avoiding crowds, wearing a mask, or choosing quieter times at the gym. But, if precautions are taken, the benefits of movement far outweigh the risks.
Benefits of keeping active:
In one of our pilot studies, people with CLL who had not yet started treatment showed smaller increases in tumour cell counts after 12 weeks of exercise. Their immune systems also appeared more robust, with stronger responses to abnormal cells. This research is still in its early stages, but it's encouraging to see that exercise doesn't appear to accelerate disease progression – and might even help to slow it. The biggest improvements were seen in people who started off with the worst symptoms or poorest physical condition.
In other words, those with the most to gain, gained the most. Older adults seemed to benefit from even modest activity. People receiving treatment were generally less active and reported lower quality of life than those who weren't, but their symptom levels were similar. That suggests physical activity might offer especially meaningful benefits for people going through treatment.
Exercise is already a well-established part of care for people with solid tumours such as breast or bowel cancer. What's different about CLL is that many people don't receive treatment for years – yet still experience symptoms and lower quality of life.
Our study shows that physical activity matters just as much for this group. Whether someone is on active monitoring or undergoing treatment, staying active can help ease symptoms, boost energy and improve daily life. It's a powerful reminder that even small steps can make a big difference and that living well with CLL isn't just about waiting for treatment. It's about reclaiming strength and mobility, one movement at a time.
(The writer is from University of Surrey)

Hashtags

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca's CLL Therapy Study in Russia: Real-World Insights and Market Impact
AstraZeneca's CLL Therapy Study in Russia: Real-World Insights and Market Impact

Globe and Mail

timea day ago

  • Globe and Mail

AstraZeneca's CLL Therapy Study in Russia: Real-World Insights and Market Impact

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is conducting an observational study titled 'Observational Retrospective-Prospective Study on CLL Therapy Approaches in Russia' to explore therapy approaches for Chronic Lymphocytic Leukemia (CLL) in a real-world setting. The study aims to gather data on treatment practices without introducing new interventions, focusing on understanding current clinical practices and patient outcomes. This non-interventional study involves no specific treatment but rather observes existing therapeutic approaches for CLL/SLL. The study will collect data from approximately 6,000 patients, assessing their treatment regimens and outcomes as per routine clinical practice. The study employs a cohort observational model with a prospective time perspective, spanning 24 months. It involves baseline, interim, and final visits to collect data, ensuring compliance with local regulatory requirements. The study commenced on October 29, 2021, with an anticipated completion date in 2025. The most recent update was submitted on July 24, 2025, indicating ongoing data collection and analysis. For investors, this study underscores AstraZeneca's commitment to understanding real-world treatment landscapes, potentially influencing its market position in the oncology sector. The findings could impact investor sentiment and stock performance, especially in comparison to competitors focusing on innovative CLL treatments. The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.

Zydus Lifesciences gets tentative approval from USFDA for Ibrutinib tablets
Zydus Lifesciences gets tentative approval from USFDA for Ibrutinib tablets

Business Upturn

time4 days ago

  • Business Upturn

Zydus Lifesciences gets tentative approval from USFDA for Ibrutinib tablets

Zydus Lifesciences has received tentative approval from the USFDA to market Ibrutinib tablets in the 140 mg, 280 mg, and 420 mg strengths in the U.S. market. The drug is a generic version of Imbruvica® and is used in treating adult patients with Chronic Lymphocytic Leukaemia (CLL)/Small Lymphocytic Lymphoma (SLL) with 17p deletion, as well as Waldenstrom's Macroglobulinemia (WM). The tablets will be manufactured at Zydus' SEZ facility in Ahmedabad. According to IQVIA (MAT May 2025), Ibrutinib tablets clocked annual sales of USD 2.15 billion in the U.S. With this, Zydus now holds 420 approvals and has filed 484 ANDAs since it began filings in FY 2003-04. In the meantime, Zydus Lifesciences shares opened today at ₹962.95 and, at the time of writing, touched a high of ₹976.60 during the session. The stock also hit a low of ₹960.15 in intraday trade. Over the past year, Zydus shares have seen a 52-week high of ₹1,324.30 and a low of ₹795.00. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at

Novel Agents Transform Double-Refractory CLL Care
Novel Agents Transform Double-Refractory CLL Care

Medscape

time4 days ago

  • Medscape

Novel Agents Transform Double-Refractory CLL Care

TOPLINE: Noncovalent Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib and chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel have gained FDA approval for double-refractory chronic lymphocytic leukemia (CLL). Novel BTK-directed therapies and T-cell-engaging bispecific antibodies demonstrate promising responses in early-phase trials for pretreated CLL. METHODOLOGY: Researchers conducted a comprehensive review of mechanisms responsible for resistance to covalent BTK inhibitors and B-cell lymphoma 2 inhibitor (BCL-2i) venetoclax in CLL. Analysis included evaluation of recent evidence supporting novel and emerging agent classes, including noncovalent BTK inhibitors, CAR T-cell therapy, and T-cell-engaging bispecific antibodies. Investigators examined treatment strategies incorporating these therapies in patients with double-refractory disease, considering variability in access to novel therapies and clinical trials. TAKEAWAY: Pirtobrutinib demonstrated an overall response rate of 72% in patients with chronic lymphocytic leukemia, with a median progression-free survival of 14 months compared with 8.7 months for control therapies. Lisocabtagene maraleucel achieved an overall response rate of 44% in double-refractory patients, with grade ≥ 3 cytokine release syndrome occurring in 8% and neurologic events in 19% of patients. BTK degraders showed promising early results, with BGB-16673 achieving responses in heavily pretreated patients, most of whom (92%) were exposed to covalent BTK inhibitors and BCL-2i. Epcoritamab demonstrated an overall response rate of 53% in double-exposed patients, with a complete response rate of 37% and undetectable measurable residual disease in two thirds of responders. IN PRACTICE: 'Within the current regulatory environment, either ncBTKi [noncovalent BTK inhibitor] or CAR T-cell therapy should be considered as first-line management for double-refractory disease, with the choice individualized based on disease stage, BTK mutational status, toxicity from prior therapies, performance status, comorbidities, and geographic and financial constraints,' the authors of the study wrote. SOURCE: This study was led by Brian T. Grainger of Sir Charles Gairdner Hospital in Nedlands, Australia. It was published online in Blood. LIMITATIONS: The literature describing CLL in the post-covalent BTK inhibitor and BCL-2i setting varies in criteria used to identify double-refractory patients, complicating assessment of disease prevalence and prognosis. Additionally, there were limited prospective data for outcomes following one class of targeted agent after disease progression on the other. DISCLOSURES: Philip A. Thompson disclosed relationships with AbbVie, Ascentage Pharma, AstraZeneca, BeiGene, Genentech, Genmab, Janssen Pharmaceuticals, Eli Lilly and Company, Merck, Adaptive Biotechnologies, Roche, and Sana Biotechnology. Additional disclosures were noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store